Tumor-infiltrating lymphocytes

Applied sciences
Biological engineering
Biomedical engineering
Genetic engineering

About
Privacy
Disclaimer

Graph Chatbot

Related publications (31)

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

George Coukos, Florian Huber, Stéphanie Tissot, Johanna Pauline Chiffelle, Alexandre Harari

T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specifi ...

2021

Neutrophils in the era of immune checkpoint blockade

Etienne Meylan, Julien Robert Rémi Faget

The immune checkpoint blockade-based immunotherapies are revolutionizing cancer management. Tumor-associated neutrophils (TANs) were recently highlighted to have a pivotal role in modulating the tumor microenvironment and the antitumor immune response. How ...

BMJ PUBLISHING GROUP2021

An autonomous microfluidic device for identification and analysis of individual clinically-relevant mammalian cells

Fabien Louis Claude Robert Jammes

Cancer represents one of the major public health challenges worldwide, representing more than 25% of all deaths in the European Union in 2014. It affects a large and growing part of the general population, with the National Cancer Institute (NCI) estimatin ...

EPFL2021

Enhancing T-cell response in cancer immunotherapy using nanoparticles

Cristiana Berti

Immunotherapy has been used in oncology in order to awaken the immune system of the patient against cancer. Within this promising field is emerging the use of therapeutic cancer vaccines, using tumor specific antigens to stimulate dendritic cells (DCs) ex ...

EPFL2021

Il10/fc fusion proteins useful as enhancers of immunotherapies

Li Tang, Yugang Guo, Yuqing Xie

The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof. ...

2021

Targeting LRG1 boosts immunotherapy

Michele De Palma, Amanda Waite Lund

Vascular normalization therapy has the potential to facilitate drug delivery and lymphocyte infiltration in tumors. Yet, optimal targets and dosage regimens remain elusive. In this issue of Med, O’Connor et al. show that inhibition of LRG1 stabilizes the t ...

2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Michele De Palma, Nadine Fournier, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Gael Luis Boivin, Amaia Martinez Usatorre, Alan Nicolas Thierry Guichard

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Cytokine engineering for targeted cancer immunotherapy

Li Tang, Lucia Bonati

Cytokines are key modulators of the immune responses and represent promising therapeutics for a variety of cancers. However, successful translation of cytokine-based therapy to the clinic is limited by, among others, severe toxicities and lack of efficacy ...

2021

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer

Hatice Altug, Alexander Mathis, George Coukos, Xiaokang Li, Yen-Cheng Liu, David Gfeller, Pedro Romero, Alexandre Harari, Amélie Cachot, Margaux Saillard, Georg Alexander Rockinger

CD4 T cells have been implicated in cancer immunity for their helper functions. Moreover, their direct cytotoxic potential has been shown in some patients with cancer. Here, by mining single-cell RNA-seq datasets, we identified CD4 T cell clusters displayi ...

2021

Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model

Gabriele Galliverti, Vincent Roh

High-risk human papillomavirus (HPV) encoding E6/E7-HPV oncogenes are responsible for a subgroup of head and neck squamous-cell carcinoma (HNSCC) and thus therapeutic E7-vaccines may be used to control HPV+HNSCC tumors. Herein we investigated the effects o ...

2021

Bioengineering Methods to Improve in vitro Adoptive Cell Therapy based on Tumor-Infiltrating Lymphocytes

François Réal Rivest

Cancer is one of the biggest medical challenges of our times, with a devastating impact across all social categories. Accordingly, considerable efforts are geared towards improving the standard of care. Among them, immunotherapy, which relies on the immune ...

EPFL2020

Page 2 of 2